Published: January 2023 | Report Code: 11991 | Available Format: PDF | Pages: 190
Chapter 1. Research Scope
1.1. Research Objectives
1.2. Market Definition
1.3. Analysis Period
1.4. Market Size Breakdown by Segment
1.4.1. Market size breakdown, by type
1.4.2. Market size breakdown, by vector type
1.4.3. Market size breakdown, by application
1.4.4. Market size breakdown, by end user
1.4.5. Market size breakdown, by region
1.5. Market Data Reporting Unit
1.5.1. Value
1.6. Key Stakeholders
Chapter 2. Research Methodology
2.1. Secondary Research
2.1.1. Paid
2.1.2. Unpaid
2.1.3. P&S Intelligence database
2.2. Primary Research
2.3. Market Size Estimation
2.4. Data Triangulation
2.5. Currency Conversion Rates
2.6. Assumptions for the Study
2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Voice of Industry Experts/KOLs
Chapter 5. Market Indicators
Chapter 6. Industry Outlook
6.1. Market Dynamics
6.1.1. Trends
6.1.2. Drivers
6.1.3. Restraints/challenges
6.1.4. Impact analysis of drivers/restraints
6.2. Impact of COVID-19
6.3. Porter’s Five Forces Analysis
6.3.1. Bargaining power of buyers
6.3.2. Bargaining power of suppliers
6.3.3. Threat of new entrants
6.3.4. Intensity of rivalry
6.3.5. Threat of substitutes
Chapter 7. Global Market
7.1. Overview
7.2. Market Revenue, by Type (2017–2030)
7.3. Market Revenue, by Vector Type (2017–2030)
7.3.1. Viral-vector gene therapy market revenue, by type (2017–2030)
7.4. Market Revenue, by Application (2017–2030)
7.5. Market Revenue, by End User (2017–2030)
7.6. Market Revenue, by Region (2017–2030)
Chapter 8. North America Market
8.1. Overview
8.2. Market Revenue, by Type (2017–2030)
8.3. Market Revenue, by Vector Type (2017–2030)
8.3.1. Viral-vector gene therapy market revenue, by type (2017–2030)
8.4. Market Revenue, by Application (2017–2030)
8.5. Market Revenue, by End User (2017–2030)
8.6. Market Revenue, by Country (2017–2030)
Chapter 9. Europe Market
9.1. Overview
9.2. Market Revenue, by Type (2017–2030)
9.3. Market Revenue, by Vector Type (2017–2030)
9.3.1. Viral-vector gene therapy market revenue, by type (2017–2030)
9.4. Market Revenue, by Application (2017–2030)
9.5. Market Revenue, by End User (2017–2030)
9.6. Market Revenue, by Country (2017–2030)
Chapter 10. APAC Market
10.1. Overview
10.2. Market Revenue, by Type (2017–2030)
10.3. Market Revenue, by Vector Type (2017–2030)
10.3.1. Viral-vector gene therapy market revenue, by type (2017–2030)
10.4. Market Revenue, by Application (2017–2030)
10.5. Market Revenue, by End User (2017–2030)
10.6. Market Revenue, by Country (2017–2030)
Chapter 11. LATAM Market
11.1. Overview
11.2. Market Revenue, by Type (2017–2030)
11.3. Market Revenue, by Vector Type (2017–2030)
11.3.1. Viral-vector gene therapy market revenue, by type (2017–2030)
11.4. Market Revenue, by Application (2017–2030)
11.5. Market Revenue, by End User (2017–2030)
11.6. Market Revenue, by Country (2017–2030)
Chapter 12. MEA Market
12.1. Overview
12.2. Market Revenue, by Type (2017–2030)
12.3. Market Revenue, by Vector Type (2017–2030)
12.3.1. Viral-vector gene therapy market revenue, by type (2017–2030)
12.4. Market Revenue, by Application (2017–2030)
12.5. Market Revenue, by End User (2017–2030)
12.6. Market Revenue, by Country (2017–2030)
Chapter 13. Competitive Landscape
13.1. List of Market Players and Their Offerings
13.2. Competitive Benchmarking of Key Players
13.3. Product Benchmarking of Key Players
13.4. Recent Strategic Developments
Chapter 14. Company Profiles
14.1. Biogen Inc.
14.1.1. Business overview
14.1.2. Product and service offerings
14.1.3. Key financial summary
14.2. Sarepta Therapeutics Inc.
14.2.1. Business overview
14.2.2. Product and service offerings
14.2.3. Key financial summary
14.3. Gilead Sciences Inc.
14.3.1. Business overview
14.3.2. Product and service offerings
14.3.3. Key financial summary
14.4. Amgen Inc.
14.4.1. Business overview
14.4.2. Product and service offerings
14.4.3. Key financial summary
14.5. Novartis AG
14.5.1. Business overview
14.5.2. Product and service offerings
14.5.3. Key financial summary
14.6. Orchard Therapeutics plc
14.6.1. Business overview
14.6.2. Product and service offerings
14.6.3. Key financial summary
14.7. AGC Inc.
14.7.1. Business overview
14.7.2. Product and service offerings
14.7.3. Key financial summary
14.8. bluebird bio Inc.
14.8.1. Business overview
14.8.2. Product and service offerings
14.8.3. Key financial summary
14.9. Dynavax Technologies Corporation
14.9.1. Business overview
14.9.2. Product and service offerings
14.9.3. Key financial summary
14.10. AnGes Inc.
14.10.1. Business overview
14.10.2. Product and service offerings
14.10.3. Key financial summary
14.11. Lonza Group Ltd.
14.11.1. Business overview
14.11.2. Product and service offerings
14.11.3. Key financial summary
14.12. BioMarin Pharmaceutical Inc.
14.12.1. Business overview
14.12.2. Product and service offerings
14.12.3. Key financial summary
14.13. American Gene Technologies Inc.
14.13.1. Business overview
14.13.2. Product and service offerings
14.14. Astellas Pharma Inc.
14.14.1. Business overview
14.14.2. Product and service offerings
14.14.3. Key financial summary
14.15. Cellectis S.A.
14.15.1. Business overview
14.15.2. Product and service offerings
14.15.3. Key financial summary
Chapter 15. Appendix
15.1. Abbreviations
15.2. Sources and References
15.3. Related Reports
LIST OF TABLES
TABLE 1 ANALYSIS PERIOD OF THE STUDY
TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS
TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS
TABLE 4 GLOBAL GENE THERAPY MARKET, BY TYPE, $M (2017–2022)
TABLE 5 GLOBAL GENE THERAPY MARKET, BY TYPE, $M (2023–2026)
TABLE 6 GLOBAL GENE THERAPY MARKET, BY TYPE, $M (2027–2030)
TABLE 7 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2022)
TABLE 8 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, $M (2023–2026)
TABLE 9 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, $M (2027–2030)
TABLE 10 GLOBAL VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2017–2022)
TABLE 11 GLOBAL VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2023–2026)
TABLE 12 GLOBAL VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2027–2030)
TABLE 13 GLOBAL GENE THERAPY MARKET, BY APPLICATION, $M (2017–2022)
TABLE 14 GLOBAL GENE THERAPY MARKET, BY APPLICATION, $M (2023–2026)
TABLE 15 GLOBAL GENE THERAPY MARKET, BY APPLICATION, $M (2027–2030)
TABLE 16 GLOBAL GENE THERAPY MARKET, BY END USER, $M (2017–2022)
TABLE 17 GLOBAL GENE THERAPY MARKET, BY END USER, $M (2023–2026)
TABLE 18 GLOBAL GENE THERAPY MARKET, BY END USER, $M (2027–2030)
TABLE 19 GLOBAL GENE THERAPY MARKET, BY REGION, $M (2017–2022)
TABLE 20 GLOBAL GENE THERAPY MARKET, BY REGION, $M (2023–2026)
TABLE 21 GLOBAL GENE THERAPY MARKET, BY REGION, $M (2027–2030)
TABLE 22 NORTH AMERICA GENE THERAPY MARKET, BY TYPE, $M (2017–2022)
TABLE 23 NORTH AMERICA GENE THERAPY MARKET, BY TYPE, $M (2023–2026)
TABLE 24 NORTH AMERICA GENE THERAPY MARKET, BY TYPE, $M (2027–2030)
TABLE 25 NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2022)
TABLE 26 NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2023–2026)
TABLE 27 NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2027–2030)
TABLE 28 NORTH AMERICA VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2017–2022)
TABLE 29 NORTH AMERICA VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2023–2026)
TABLE 30 NORTH AMERICA VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2027–2030)
TABLE 31 NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, $M (2017–2022)
TABLE 32 NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, $M (2023–2026)
TABLE 33 NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, $M (2027–2030)
TABLE 34 NORTH AMERICA GENE THERAPY MARKET, BY END USER, $M (2017–2022)
TABLE 35 NORTH AMERICA GENE THERAPY MARKET, BY END USER, $M (2023–2026)
TABLE 36 NORTH AMERICA GENE THERAPY MARKET, BY END USER, $M (2027–2030)
TABLE 37 NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, $M (2017–2022)
TABLE 38 NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, $M (2023–2026)
TABLE 39 NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, $M (2027–2030)
TABLE 40 EUROPE GENE THERAPY MARKET, BY TYPE, $M (2017–2022)
TABLE 41 EUROPE GENE THERAPY MARKET, BY TYPE, $M (2023–2026)
TABLE 42 EUROPE GENE THERAPY MARKET, BY TYPE, $M (2027–2030)
TABLE 43 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2022)
TABLE 44 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, $M (2023–2026)
TABLE 45 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, $M (2027–2030)
TABLE 46 EUROPE VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2017–2022)
TABLE 47 EUROPE VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2023–2026)
TABLE 48 EUROPE VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2027–2030)
TABLE 49 EUROPE GENE THERAPY MARKET, BY APPLICATION, $M (2017–2022)
TABLE 50 EUROPE GENE THERAPY MARKET, BY APPLICATION, $M (2023–2026)
TABLE 51 EUROPE GENE THERAPY MARKET, BY APPLICATION, $M (2027–2030)
TABLE 52 EUROPE GENE THERAPY MARKET, BY END USER, $M (2017–2022)
TABLE 53 EUROPE GENE THERAPY MARKET, BY END USER, $M (2023–2026)
TABLE 54 EUROPE GENE THERAPY MARKET, BY END USER, $M (2027–2030)
TABLE 55 EUROPE GENE THERAPY MARKET, BY COUNTRY, $M (2017–2022)
TABLE 56 EUROPE GENE THERAPY MARKET, BY COUNTRY, $M (2023–2026)
TABLE 57 EUROPE GENE THERAPY MARKET, BY COUNTRY, $M (2027–2030)
TABLE 58 APAC GENE THERAPY MARKET, BY TYPE, $M (2017–2022)
TABLE 59 APAC GENE THERAPY MARKET, BY TYPE, $M (2023–2026)
TABLE 60 APAC GENE THERAPY MARKET, BY TYPE, $M (2027–2030)
TABLE 61 APAC GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2022)
TABLE 62 APAC GENE THERAPY MARKET, BY VECTOR TYPE, $M (2023–2026)
TABLE 63 APAC GENE THERAPY MARKET, BY VECTOR TYPE, $M (2027–2030)
TABLE 64 APAC VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2017–2022)
TABLE 65 APAC VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2023–2026)
TABLE 66 APAC VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2027–2030)
TABLE 67 APAC GENE THERAPY MARKET, BY APPLICATION, $M (2017–2022)
TABLE 68 APAC GENE THERAPY MARKET, BY APPLICATION, $M (2023–2026)
TABLE 69 APAC GENE THERAPY MARKET, BY APPLICATION, $M (2027–2030)
TABLE 70 APAC GENE THERAPY MARKET, BY END USER, $M (2017–2022)
TABLE 71 APAC GENE THERAPY MARKET, BY END USER, $M (2023–2026)
TABLE 72 APAC GENE THERAPY MARKET, BY END USER, $M (2027–2030)
TABLE 73 APAC GENE THERAPY MARKET, BY COUNTRY, $M (2017–2022)
TABLE 74 APAC GENE THERAPY MARKET, BY COUNTRY, $M (2023–2026)
TABLE 75 APAC GENE THERAPY MARKET, BY COUNTRY, $M (2027–2030)
TABLE 76 LATAM GENE THERAPY MARKET, BY TYPE, $M (2017–2022)
TABLE 77 LATAM GENE THERAPY MARKET, BY TYPE, $M (2023–2026)
TABLE 78 LATAM GENE THERAPY MARKET, BY TYPE, $M (2027–2030)
TABLE 79 LATAM GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2022)
TABLE 80 LATAM GENE THERAPY MARKET, BY VECTOR TYPE, $M (2023–2026)
TABLE 81 LATAM GENE THERAPY MARKET, BY VECTOR TYPE, $M (2027–2030)
TABLE 82 LATAM VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2017–2022)
TABLE 83 LATAM VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2023–2026)
TABLE 84 LATAM VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2027–2030)
TABLE 85 LATAM GENE THERAPY MARKET, BY APPLICATION, $M (2017–2022)
TABLE 86 LATAM GENE THERAPY MARKET, BY APPLICATION, $M (2023–2026)
TABLE 87 LATAM GENE THERAPY MARKET, BY APPLICATION, $M (2027–2030)
TABLE 88 LATAM GENE THERAPY MARKET, BY END USER, $M (2017–2022)
TABLE 89 LATAM GENE THERAPY MARKET, BY END USER, $M (2023–2026)
TABLE 90 LATAM GENE THERAPY MARKET, BY END USER, $M (2027–2030)
TABLE 91 LATAM GENE THERAPY MARKET, BY COUNTRY, $M (2017–2022)
TABLE 92 LATAM GENE THERAPY MARKET, BY COUNTRY, $M (2023–2026)
TABLE 93 LATAM GENE THERAPY MARKET, BY COUNTRY, $M (2027–2030)
TABLE 94 MEA GENE THERAPY MARKET, BY TYPE, $M (2017–2022)
TABLE 95 MEA GENE THERAPY MARKET, BY TYPE, $M (2023–2026)
TABLE 96 MEA GENE THERAPY MARKET, BY TYPE, $M (2027–2030)
TABLE 97 MEA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2022)
TABLE 98 MEA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2023–2026)
TABLE 99 MEA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2027–2030)
TABLE 100 MEA VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2017–2022)
TABLE 101 MEA VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2023–2026)
TABLE 102 MEA VIRAL-VECTOR GENE THERAPY MARKET, BY TYPE, $M (2027–2030)
TABLE 103 MEA GENE THERAPY MARKET, BY APPLICATION, $M (2017–2022)
TABLE 104 MEA GENE THERAPY MARKET, BY APPLICATION, $M (2023–2026)
TABLE 105 MEA GENE THERAPY MARKET, BY APPLICATION, $M (2027–2030)
TABLE 106 MEA GENE THERAPY MARKET, BY END USER, $M (2017–2022)
TABLE 107 MEA GENE THERAPY MARKET, BY END USER, $M (2023–2026)
TABLE 108 MEA GENE THERAPY MARKET, BY END USER, $M (2027–2030)
TABLE 109 MEA GENE THERAPY MARKET, BY COUNTRY, $M (2017–2022)
TABLE 110 MEA GENE THERAPY MARKET, BY COUNTRY, $M (2023–2026)
TABLE 111 MEA GENE THERAPY MARKET, BY COUNTRY, $M (2027–2030)
TABLE 112 BIOGEN INC. – AT A GLANCE
TABLE 113 BIOGEN INC. – KEY FINANCIAL SUMMARY
TABLE 114 SAREPTA THERAPEUTICS INC. – AT A GLANCE
TABLE 115 SAREPTA THERAPEUTICS INC. – KEY FINANCIAL SUMMARY
TABLE 116 GILEAD SCIENCES INC. – AT A GLANCE
TABLE 117 GILEAD SCIENCES INC. – KEY FINANCIAL SUMMARY
TABLE 118 AMGEN INC. – AT A GLANCE
TABLE 119 AMGEN INC. – KEY FINANCIAL SUMMARY
TABLE 120 NOVARTIS AG – AT A GLANCE
TABLE 121 NOVARTIS AG – KEY FINANCIAL SUMMARY
TABLE 122 ORCHARD THERAPEUTICS PLC – AT A GLANCE
TABLE 123 ORCHARD THERAPEUTICS PLC – KEY FINANCIAL SUMMARY
TABLE 124 AGC INC. – AT A GLANCE
TABLE 125 AGC INC. – KEY FINANCIAL SUMMARY
TABLE 126 BLUEBIRD BIO INC. – AT A GLANCE
TABLE 127 BLUEBIRD BIO INC. – KEY FINANCIAL SUMMARY
TABLE 128 DYNAVAX TECHNOLOGIES CORPORATION – AT A GLANCE
TABLE 129 DYNAVAX TECHNOLOGIES CORPORATION – KEY FINANCIAL SUMMARY
TABLE 130 ANGES INC. – AT A GLANCE
TABLE 131 ANGES INC. – KEY FINANCIAL SUMMARY
TABLE 132 LONZA GROUP LTD. – AT A GLANCE
TABLE 133 LONZA GROUP LTD. – KEY FINANCIAL SUMMARY
TABLE 134 BIOMARIN PHARMACEUTICAL INC. – AT A GLANCE
TABLE 135 BIOMARIN PHARMACEUTICAL INC. – KEY FINANCIAL SUMMARY
TABLE 136 AMERICAN GENE TECHNOLOGIES INC. – AT A GLANCE
TABLE 137 ASTELLAS PHARMA INC. – AT A GLANCE
TABLE 138 ASTELLAS PHARMA INC. – KEY FINANCIAL SUMMARY
TABLE 139 CELLECTIS S.A. – AT A GLANCE
TABLE 140 CELLECTIS S.A. – KEY FINANCIAL SUMMARY
LIST OF FIGURES
FIG 1 MARKET SIZE BREAKDOWN BY SEGMENT
FIG 2 RESEARCH METHODOLOGY
FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY REGION
FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY DESIGNATION
FIG 5 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE
FIG 6 DATA TRIANGULATION APPROACH
FIG 7 CURRENCY CONVERSION RATES FOR USD (2022)
FIG 8 GLOBAL GENE THERAPY MARKET SUMMARY
FIG 9 BARGAINING POWER OF BUYERS
FIG 10 BARGAINING POWER OF SUPPLIERS
FIG 11 THREAT OF NEW ENTRANTS
FIG 12 INTENSITY OF RIVALRY
FIG 13 THREAT OF SUBSTITUTES
FIG 14 GLOBAL GENE THERAPY MARKET SNAPSHOT
FIG 15 GLOBAL GENE THERAPY MARKET, BY TYPE, $M (2017–2030)
FIG 16 GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2030)
FIG 17 GLOBAL GENE THERAPY MARKET, BY APPLICATION, $M (2017–2030)
FIG 18 GLOBAL GENE THERAPY MARKET, BY END USER, $M (2017–2030)
FIG 19 MAJOR WORLDWIDE MARKETS FOR GENE THERAPY, $M
FIG 20 NORTH AMERICA GENE THERAPY MARKET SNAPSHOT
FIG 21 NORTH AMERICA GENE THERAPY MARKET, BY TYPE, $M (2017–2030)
FIG 22 NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2030)
FIG 23 NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, $M (2017–2030)
FIG 24 NORTH AMERICA GENE THERAPY MARKET, BY END USER, $M (2017–2030)
FIG 25 NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, $M (2017–2030)
FIG 26 EUROPE GENE THERAPY MARKET SNAPSHOT
FIG 27 EUROPE GENE THERAPY MARKET, BY TYPE, $M (2017–2030)
FIG 28 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2030)
FIG 29 EUROPE GENE THERAPY MARKET, BY APPLICATION, $M (2017–2030)
FIG 30 EUROPE GENE THERAPY MARKET, BY END USER, $M (2017–2030)
FIG 31 EUROPE GENE THERAPY MARKET, BY COUNTRY, $M (2017–2030)
FIG 32 APAC GENE THERAPY MARKET SNAPSHOT
FIG 33 APAC GENE THERAPY MARKET, BY TYPE, $M (2017–2030)
FIG 34 APAC GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2030)
FIG 35 APAC GENE THERAPY MARKET, BY APPLICATION, $M (2017–2030)
FIG 36 APAC GENE THERAPY MARKET, BY END USER, $M (2017–2030)
FIG 37 APAC GENE THERAPY MARKET, BY COUNTRY, $M (2017–2030)
FIG 38 LATAM GENE THERAPY MARKET SNAPSHOT
FIG 39 LATAM GENE THERAPY MARKET, BY TYPE, $M (2017–2030)
FIG 40 LATAM GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2030)
FIG 41 LATAM GENE THERAPY MARKET, BY APPLICATION, $M (2017–2030)
FIG 42 LATAM GENE THERAPY MARKET, BY END USER, $M (2017–2030)
FIG 43 LATAM GENE THERAPY MARKET, BY COUNTRY, $M (2017–2030)
FIG 44 MEA GENE THERAPY MARKET SNAPSHOT
FIG 45 MEA GENE THERAPY MARKET, BY TYPE, $M (2017–2030)
FIG 46 MEA GENE THERAPY MARKET, BY VECTOR TYPE, $M (2017–2030)
FIG 47 MEA GENE THERAPY MARKET, BY APPLICATION, $M (2017–2030)
FIG 48 MEA GENE THERAPY MARKET, BY END USER, $M (2017–2030)
FIG 49 MEA GENE THERAPY MARKET, BY COUNTRY, $M (2017–2030)
FIG 50 BIOGEN INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 51 SAREPTA THERAPEUTICS INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 52 GILEAD SCIENCES INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 53 AMGEN INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 54 NOVARTIS AG – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 55 ORCHARD THERAPEUTICS PLC – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 56 AGC INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 57 BLUEBIRD BIO INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 58 DYNAVAX TECHNOLOGIES CORPORATION – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 59 ANGES INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 60 LONZA GROUP LTD. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 61 BIOMARIN PHARMACEUTICAL INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 62 ASTELLAS PHARMA INC. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 63 CELLECTIS S.A. – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
Get a bespoke market intelligence solution
Want a report tailored exactly to your business strategy?
Request CustomizationWant an insight-rich discussion with the report author?
Speak to AnalystOur dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws